Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 7/20 | 0.53 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549231 | 0.84 | HTR4 (0.52) | GAAHTR3AHTR4 | |
| SCHEMBL3543959 | 0.83 | GAA (0.52) | GAAHTR3A | |
| SCHEMBL1781864 | 0.81 | ACKR3 (0.55) | HRH3CRBN | |
| SCHEMBL13498283 | 0.81 | CRBN (0.57) | GAAHRH3CRBN | |
| SCHEMBL31567826 | 0.80 | CRBN (0.60) | HRH3CRBN | |
| SCHEMBL7987541 | 0.80 | CRBN (0.60) | HRH3CRBN | |
| SCHEMBL3544464 | 0.80 | HTR4 (0.61) | GAAHTR3AHTR4 | |
| SCHEMBL3539091 | 0.80 | HTR4 (0.61) | GAAHTR3AHTR4 | |
| SCHEMBL3543722 | 0.79 | MEN1 (0.55) | HTR3AHRH3 | |
| SCHEMBL3543720 | 0.79 | MEN1 (0.55) | HTR3AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | GAA 159/4885HTR3A 2998/4885HTR4 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.